Retrospective, mono-centric post-market clinical follow-up study on the use of Cerasorb® Foam for socket preservation in dental surgery - ReSORB

curasan AG0 个研究点目标入组 54 人开始时间: 2022年5月9日最近更新: 2024年8月19日

试验速览

暂无简介。

•Patients who have been treated according to the intended use and instructions for use of Cerasorb Foam and have undergone dental surgery for filling and reconstruction of two-walled and multi-walled non-infected bone, with existing documentation for:
•- diagnosis of tooth not worthy of preservation
•- surgical treatment of tooth extraction, including digital volume tomography (DVT) measurement of dental alveolus according to AWMF guidelines 083-005 and 083-011
•- removal of stitches (safety visit)
•- implant placement with prior DVT follow-up measurement of dental alveolus

•Patients whose diagnosis does not fall within the indications, or whose medical condition is one of the contraindications for Cerasorb Foam, which are:
•- Acute and chronic infections in the operative field
•- Severe metabolic disorders, such as severe, uncontrolled, or poorly controlled diabetes or bone diseases which impair bone or wound healing
•- Disorders of calcium metabolism - Steroid treatment - Drugs that interfere with calcium metabolism
•- Immunosuppressive therapy
•- Endocrine bone disease
•- Radiation therapy
•- Nicotine abuse
•- Known allergies to porcine collagen or other protein allergies.

发起方

curasan AG